Last: | $0.5803 |
---|---|
Change Percent: | 1.57% |
Open: | $0.57 |
Close: | $0.5803 |
High: | $0.583 |
Low: | $0.5699 |
Volume: | 197,858 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.5803 | $0.57 | $0.5803 | $0.583 | $0.5699 | 197,858 | 07-05-2024 |
$0.5791 | $0.579 | $0.5791 | $0.5797 | $0.5679 | 282,095 | 07-04-2024 |
$0.5791 | $0.579 | $0.5791 | $0.5797 | $0.5679 | 282,095 | 07-03-2024 |
$0.57 | $0.58 | $0.57 | $0.593 | $0.538 | 903,509 | 07-02-2024 |
$0.5836 | $0.6012 | $0.5836 | $0.6298 | $0.583 | 1,049,205 | 07-01-2024 |
$0.6 | $0.64 | $0.6 | $0.6444 | $0.5968 | 9,811,566 | 06-28-2024 |
$0.6343 | $0.638 | $0.6343 | $0.6592 | $0.6311 | 718,378 | 06-27-2024 |
$0.6311 | $0.6509 | $0.6311 | $0.66 | $0.6311 | 501,724 | 06-26-2024 |
$0.6563 | $0.65 | $0.6563 | $0.6643 | $0.6401 | 951,502 | 06-25-2024 |
$0.65 | $0.635 | $0.65 | $0.66 | $0.635 | 522,846 | 06-24-2024 |
$0.6428 | $0.6616 | $0.6428 | $0.6616 | $0.6318 | 743,869 | 06-21-2024 |
$0.6616 | $0.664 | $0.6616 | $0.686 | $0.65 | 179,800 | 06-20-2024 |
$0.6549 | $0.661 | $0.6549 | $0.6884 | $0.6454 | 595,251 | 06-19-2024 |
$0.6549 | $0.661 | $0.6549 | $0.6884 | $0.6454 | 595,251 | 06-18-2024 |
$0.664 | $0.685 | $0.664 | $0.6985 | $0.655 | 304,153 | 06-17-2024 |
$0.6825 | $0.6905 | $0.6825 | $0.7087 | $0.671 | 205,605 | 06-14-2024 |
$0.6942 | $0.7133 | $0.6942 | $0.718399 | $0.6832 | 214,288 | 06-13-2024 |
$0.7099 | $0.7247 | $0.7099 | $0.754 | $0.7005 | 478,081 | 06-12-2024 |
$0.7085 | $0.71 | $0.7085 | $0.71 | $0.68 | 180,079 | 06-11-2024 |
$0.7194 | $0.679 | $0.7194 | $0.725 | $0.6763 | 558,872 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...